論文

査読有り
2019年7月15日

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.

Internal medicine (Tokyo, Japan)
  • Masashi Kono
  • ,
  • Toshiharu Sakurai
  • ,
  • Kazuki Okamoto
  • ,
  • Tomoyuki Nagai
  • ,
  • Yoriaki Komeda
  • ,
  • Hiroshi Kashida
  • ,
  • Kosuke Minaga
  • ,
  • Ken Kamata
  • ,
  • Mamoru Takenaka
  • ,
  • Satoru Hagiwara
  • ,
  • Tomohiro Watanabe
  • ,
  • Naoshi Nishida
  • ,
  • Eisuke Enoki
  • ,
  • Hiroaki Inoue
  • ,
  • Itaru Matsumura
  • ,
  • Masatoshi Kudo

58
14
開始ページ
2029
終了ページ
2033
記述言語
英語
掲載種別
DOI
10.2169/internalmedicine.2495-18

Autoimmune diseases including inflammatory bowel disease (IBD) occur in association with myelodysplastic syndrome (MDS). MDS-associated IBD frequently demonstrates a complicated course. We herein report the first case with MDS-associated IBD that was successfully treated with ustekinumab (UST), an anti-interleukin (IL) 12/23p40 monoclonal antibody. A 63-year-old man with a 7-year history of MDS was referred for examination of diarrhea, abdominal pain and fever. A blood examination revealed a marked elevation of C-reactive protein. Colonoscopy showed multiple ulcers in the terminal ileum. He was resistant to anti-tumor necrosis factor (TNF)-α antibody and azacitidine. Subsequently, UST treatment reduced colonic IL-17 and IL-6 expression and the patient currently maintains a state of remission.

リンク情報
DOI
https://doi.org/10.2169/internalmedicine.2495-18
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30996178
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702013

エクスポート
BibTeX RIS